Hypoxia-Inducible Factor1-Α (HIF1α) and Vascular Endothelial Growth Factor-A (VEGF-A) Expression in De Novo AML Patients

Document Type : Research Articles


1 HSCT Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

2 Laboratory Hematology and Blood Banking Department, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.


Background: Bone marrow hypoxia can promote leukemia progression in human cases of acute myeloid leukemia
(AML). In addition, low oxygen tension is able to regulate the expression of different genes involved in malignancy.
In this study, we hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF-A) genes were
assessed as principal regulators of hypoxia in do novo AML patients. Methods: Peripheral blood and bone marrow
samples were collected from 57 AML patients and 17 normal control subjects with informed consent. Expression of
HIF1α and VEGF-A was then evaluated using quantitative real-time PCR (Q-Real time PCR) and data were analyzed
with SPSS 16. Result: HIF1α and VEGF-A showed overexpression in AML patients compared to normal controls (P
AML-non M3 cases. Furthermore, there was a positive correlation between HIF1α and VEGF-A ( P 0.497). Conclusion: Adding to the many studies on the role of hypoxia in solid tumors, our data indicate that HIF1a
and VEGF-A overexpression also occurs in AML patients. We consider that this is possibly involved in leukemic cell
growth and therefore could be a promising target for clinical control.


Main Subjects